INTRODUCTION
Epithelioid glioblastoma (eGBM) is one of the rarest variants of GBM and recognized as a aggressive subtype in the revised 2016 World Health Organization (WHO) classification. 1 Although integrated diagnosis was introduced in the revised 2016 WHO classification, no molecular parameters that could be markers, such as mutant isocitrate dehydrogenase (IDH) in diffuse glioma, were shown for eGBM. The association with pleomorphic xanthoastrocytoma (PXA) with a similar genetic background 2 in terms of having a high rate of v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) mutation, is predicted. In addition, eGBM and PXA, especially anaplastic PXA, show overlapping histological features that are discohesive epithelioid patterns of tumor cells, perivascular and intercellular lymphocyte infiltration. Occasionally, it is difficult to distinguish these two tumors. Most eGBM are recognized as primary lesions. However, a few cases of eGBM preceded by or concomitant with lower grade precursors have been reported. [3] [4] [5] [6] [7] Taken together, these two tumors may belong to the same or Correspondence: Takuya Furuta, Department of Pathology, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan. Email: tfuruta@med.kurume-u.ac.jp very closely related category. In the present study, molecular markers such as mutations in the genes for BRAF, α-thalassemia/mental retardation syndrome X-linked (ATRX), telomerase reverse transcriptase (TERT) promotor (TERT-p), isocitrate dehydrogenases 1 and 2 (IDH1/2), histone H3 and TP53 were adopted in the histological features of both, and the new WHO classification were examined.
MATERIAL AND METHOD Tissue samples/case collection
Twenty patients were newly diagnosed with PXA (including anaplastic PXA) or eGBM at Kurume University Hospital and Kanazawa University Hospital between 1992 and 2016. This study was approved by the Medical Ethics Committee of the each institution. For the purpose of this study, patients 18 years old or younger were considered pediatric.
Histology and immunohistochemistry
Histological review was performed on 4-μm sections of formalin-fixed paraffin-embedded (FFPE) specimens based on the revised World Health Organization (WHO) criteria 1 by two neuropathologists (TF and YS). PXA showed pleomorphic appearance, in which spindled cells, mono-of multinucleated giant astrocytes and often contains cytoplasmic lipid, eosinophilic granular bodies, and lymphocyte infiltration. On the basis of PXA histology, anaplastic PXA was defined according to the 2016 WHO criteria by the presence of five or more mitoses per 10 high power fields (HPFs). As defined previously by Kleinschmidt-DeMasters et al., eGBM had to be composed in great part (more than 30-40% of the tumor) of patternless sheets of discohesive, epithelioid cells with distinct cellular borders, abundant eosinophilic cytoplasm, and central or slightly eccentric nuclei with distinct nucleoli. 8 The proportion of existing structures were scored as follows: diffuse, patchy, rare and none. Mitoses were counted per 10 HPFs. Tissue sections were immunostained using the following antibodies: ATRX (Sigma-Aldrich, St. Louis, MO, USA; 1:100 dilution), IDH1 (Dianova, Hamburg, Germany; 1:100 dilution), H3 K27 M (Millipore, Billercia, MA, USA; 1:500 dilution), integrase interactor 1 (INI1) (SMARCB1 gene product) (Abcam, Cambridge, MA, USA; 1:12 000 dilution), and p53 (clone DO-7) (Dako, Japan Co., Kyoto, Japan; 1:100 dilution). The p53 immunostain was identified as positive when greater than 10% p53 nuclear positivity was present. 9 All immunostainings were screened for internal positive or negative controls such as endothelial cells and/or trapped cortical neurons. 
DNA isolation and mutation analysis

RESULTS
The available clinical data for this study comprised patient age at operation, gender and tumor location. Twelve PXAs and eight eGBMs were eligible for the study. Two anaplastic PXAs (cases 2 and 5) arose from lower-grade PXA (cases 1 and 4). One PXA (case 4), its recurrent tumor (case 5), and one eGBM (case 19) of the cases included in this series have been the subjects of previous reports. 7, 10 Cases 15 and 16 were siblings and developed eGBM in their teens. As shown in Table 2 , there were six male (three PXAs and three eGBM) and 14 female (nine PXAs and five eGBMs) patients. Six of the cases were pediatric (three PXAs and three eGBM) and 14 (nine PXAs and five eGBM) were adult. Median ages for PXA and eGBM were 31.5 (11-78) years and 28.5 (10-78) years, respectively. Most PXAs and eGBMs occurred in the cerebral hemispheres (six temporal, four frontal, four parietal, one occipital) while two were in the cerebellum and one PXA in the pineal. The neuroradiological images were reviewed in three PXAs and four eGBMs. These tumors showed similar features that were peripheral smooth, well demarcated, contrast enhancing and localized (Fig. 1) . PXA often had single and/or multiple cysts, whereas eGBM received blood supply both internally (Fig. 1C) and externally ( Fig. 1D ) mimicking malignant meningioma. Two eGBMs (cases 19 and 20) arising from PXA showed tumor dissemination from the brainstem to the spinal cord 3-4 months after a second operation.
The histological and morphological findings are summarized in Table 2 . Immunohistochemistry was incomplete in one eGBM (case 15) due to insufficient specimen. eGBM and PXA, especially anaplastic PXA, sometimes showed the overlapping morphology featured by epithelioid pattern of tumor cells (Fig. 2) . Lower grade (WHO grade II) PXAs showed typical morphology including spindled cells variably forming fascicles, large bizarre mono-and multinucleated cells with or without lipidized cytoplasm ("xanthomatous cell"), perivascular lymphocyte cuffing, eosinophilic granular bodies (EGBs) and reticulin fiber deposit. "Malignant" PXAs showing one or more mitosis tended to have vascular proliferation and necrosis, and lacked xanthomatous cells, EGBs and reticulin fiber that reflected degenerative changes (Table 2, Fig. 2 ). All eGBM demonstrated a lot of mitoses and microvascular proliferation as seen in common GBM. Two eGBMs arising from TERT-p mutation (chr5: 1 295 228 C > T (C228T) or 1 295 250 C > T (C250T)) in two (17%) PXAs and one (13%) eGBM, respectively. No mutation at H3 G34R/V was detected. Interestingly, one PXA without BRAF V600E mutation (case 5) acquired TERT-p mutation at recurrence (Fig. 3A-D) . One eGBM (case 13) had both BRAF mutation (V600E) and TERT-p mutation (C250T) (Fig. 3E-H) and this patient followed a miserable course.
The differences and similarities between PXA and eGBM are summarized in Table 4 . Our cohort was too small to be statistically analyzed. There was no significant difference in sex, age or tumor localization. For molecular biological characteristics, p53 mutation was seen more in eGBM (7/7) than PXA (2/10) while there were no significant differences in ATRX, BRAF, H3F3A, and TERT-p. Fig. 3 "Integrated" analysis of PXA and eGBM. One PXA (case 4) without BRAF V600E mutation acquires TERTp mutation at recurrence evolving to anaplastic PXA (case 5) (A-D). A, HE staining of the first operation tumor shows tumor nests composed of spindle to epithelioid cells with eosinophilic cytoplasm. B, HE staining of the second operation tumor shows more cellular and nucleic atypia with more frequent mitosis. C and D, this BRAF mutant tumor acquires TERT-p mutation at recurrence with malignant conversion. One eGBM (case 13) harbores both BRAF and TERT-p mutations (E-H). E, HE staining of the first operation tumor shows spindle cells intermingled with slightly cohesive rounded cells with laterally positioned nuclei and eosinophilic cytoplasm and a small number of xanthomatous cells, but no eosinophilic granular body or reticulin fiber. F, the autopsy specimens of the same case demonstrates more discohesive rhabdoid pattern other than epithelioid pattern and extensive necrosis. G and H, both primary and recurrent tumors have BRAF (C) and TERT-p (D) mutations. Scale bar: 50 μm (A, B, E, F) .
DISCUSSION
eGBM and PXA exhibit some common findings on MRI: (i) contrast-enhanced solid and/or cystic; (ii) well circumscribed with no or little peritumoral edema; (iii) leptomeningeal involvement; and (iv) leptomeningeal dissemination compared with diffuse glioma at recurrence. 5, 8, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] In our case series, one eGBM (case 15, Figs 1, 3 ) totally excised at first operation has been alive for over 2 years. Some cases of eGBM demonstrated good prognosis, 8, 19 suggesting the tumors might be PXA.
Despite our small cohort, PXA tended to lose the degenerative changes such as eosinophilic granular bodies, reticulin fiber deposit, and intracellular xanthomatous changes at recurrence with malignant transformation while eGBM showed no or few degenerative changes. Anaplastic PXA also tended to lose those changes and pleomorphism turning to monotonous and/or epithelioid morphology. The degenerative changes were seen in not only in PXA but also ganglioglioma (GG) and pilocytic astrocytoma (PA). 23 At recurrence with malignant transformation of PXA, degenerative changes tended to be lost, 10, 16, [24] [25] [26] [27] while primary anaplastic PXA often had degenerative changes. 
gov).
TERT-p mutation might be involved in malignant transformation of PXA and tumorigenesis of eGBM. As shown in Figure 2 , a case of PXA (case 4) evolved to anaplastic PXA (case 5) acquiring epithelioid morphology and TERT-p mutation (C228T) at recurrence, and a case of eGBM (case 13) had both BRAF (T1799A) and TERT-p mutation (C250T). TERT-p mutation was involved in malignant conversion in meningioma and BRAF-mutated melanoma, 43, 44 and was associated with carcinogenesis of mantle cell lymphoma and hepatocellular carcinoma. 45, 46 In addition to TERT-p mutation, there might be molecules involved in tumor development and malignancy of PXA and eGBM. Comprehensive analyses with next-generation sequencing, for example, are required to understand these rare tumors in the future. eGBM occurred in de novo fashion in the majority of cases while some cases arose from lower-grade disease. 3, 5, 7, 8, 15, 20, 47 Most PXAs had developed directly from grade II to IV, but there were few anaplastic PXAs developing from grade III to IV. 12 Nobusawa et al. reported that homozygous deletion of LSAMP, a tumor suppressor gene, was associated with malignant features of eGBM containing lower-grade diffuse glioma component.
48
CDKN2A deletion in BRAF-mutated low-grade glioma (LGG) was significantly associated with malignant transformation. 49 It can be speculated that the genetic models for development and progression of eGBM and PXA include common mutation, such as BRAF, as an early event to both tumors and additional genetic alterations, such as TERT-p, LSAMP or CDKN2A, is essential for progression of PXA and development of eGBM. For example, case 13, which showed poor prognosis, had TERT-p and p53 mutations in addition to BRAF mutation, extensive necrosis, high mitotic activity and nuclear atypia, suggesting the possibility of malignant conversion from LGG previously unrecognized as a precursor lesion. However, there was no evidence to support that this tumor occurred in a secondary lesion and even in de novo fashion. On the other hand, case 14, which showed good prognosis, had BRAF and p53 mutations, and less mitotic activity, suggesting the possibility that it might be a PXA harboring p53 mutation like case 6 or 10. Further investigations and accumulation of evidence are required for clarification of these tumors. Morphologically, lower-grade PXA clearly differs from eGBM while it is difficult to discriminate malignant or malignantly converted anaplastic PXA from eGBM due to their epithelioid pattern and lack of degenerative features. Molecular biologically, PXA and eGBM belong to the same category and occur in primary and/or secondary fashion by acquiring molecular genetic abnormalities such as p53 and TERT-p on the basis of BRAF mutation. Despite small case numbers, our exploratory findings could be a foundation of future large-scale research. For the present, "integrated" diagnosis introduced to the revised WHO 2016 classification is important to understand brain tumors systematically and facilitate clinical and epidemiological studies. Of course, neuro-oncologists, neuropathologists and neurosurgeons must share clinical information such as neuroradiological findings and molecular genetic information, and work closely together in order to conduct an appropriate diagnosis.
